Key Documents

View All Documentation

Levetiracetam Racemic Mixture

Name: Levetiracetam Racemic Mixture
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(RS)-α-Ethyl-2-oxo-1-pyrrolidineacetamide, 2(RS)-(2-Oxopyrrolidin-1-yl)butyramide, Etiracetam

Select a Size

Change View

Pack Size	SKU	Availability	Price

About This Item

Empirical Formula (Hill Notation):

C₈H₁₄N₂O₂

CAS Number:

33996-58-6

Molecular Weight:

170.21

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329750034

MDL number:

MFCD00868507

Beilstein/REAXYS Number:

1529106

Pricing and availability is not currently available.

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

levetiracetam

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCC(N1CCCC1=O)C(N)=O

InChI

1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)

InChI key

HPHUVLMMVZITSG-UHFFFAOYSA-N

Description

General description

Levetiracetam racemic mixture also know as etiracetam is an stuctural analogue ethylated piracetam drug.[1]

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levetiracetam Racemic Mixture USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Levetiracetam

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item	1359404	PHR2417	Y0001253
USP 1359415 Levetiracetam Racemic Mixture	USP 1359404 Levetiracetam	Supelco PHR2417 Levetiracetam Racemic Mixture	Y0001253 Levetiracetam
grade pharmaceutical primary standard	grade pharmaceutical primary standard	grade certified reference material, pharmaceutical secondary standard	grade pharmaceutical primary standard
manufacturer/tradename USP	manufacturer/tradename USP	manufacturer/tradename -	manufacturer/tradename EDQM
format neat	format neat	format -	format neat
application(s) pharmaceutical (small molecule)	application(s) pharmaceutical (small molecule)	application(s) pharmaceutical	application(s) pharmaceutical (small molecule)
API family levetiracetam	API family levetiracetam	API family levetiracetam	API family levetiracetam

pictograms

GHS07,GHS09

signalword

Warning

hcodes

H302,H319,H411

pcodes

P264 - P273 - P280 - P301 + P312 - P305 + P351 + P338 - P337 + P313

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2

Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Augmented renal clearance of vancomycin and levetiracetam in a traumatic brain injury patient.

Aaron M Cook et al.

Neurocritical care, 19(2), 210-214 (2013-08-03)

Increased creatinine clearance and subsequent elevated antimicrobial clearance is evident in many traumatic brain injury (TBI) patients due to augmented renal clearance (ARC). Little is known about the effects of ARC on other renally-eliminated medications, such as the anti-epileptic drug

Can zinc depletion play a role in LEV-induced hair loss? Considerations from a case study.

Rocco Salvatore Calabrò et al.

Epilepsy & behavior : E&B, 29(1), 254-255 (2013-08-14)

Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents.

Radica M Stepanovic-Petrovic et al.

Anesthesiology, 120(3), 737-750 (2013-09-28)

The β-lactam antibiotic ceftriaxone stimulates glutamate transporter GLT-1 expression and is effective in neuropathic and visceral pain models. This study examined the effects of ceftriaxone and its interactions with different analgesics (ibuprofen, celecoxib, paracetamol, and levetiracetam) in somatic and visceral

View All Related Papers

Global Trade Item Number

SKU	GTIN
1359415-15MG	04061833851036

Questions

Reviews

No rating value